Ovid Therapeutics & Takeda Announce Agreement for Soticlestat

• Ovid Pharmaceuticals is eligible to receive up to $856M in payments, including a $196M upfront payment, regulatory and commercial milestone payments and tiered double-digit royalties on product sales
• Potential first-in-class therapy reduced seizure frequency in children with Dravet syndrome and Lennox-Gastaut syndrome in Phase 2 ELEKTRA study
• Original 2017 collaboration between Ovid and Takeda to conclude; Ovid will have no further development or milestone obligations
• Takeda plans to initiate Phase 3 studies in children and . . .
  
  This content is for paid subscribers.
  Please click here to subscribe or here to log in.
  Today’s Highlights

  Ovid Therapeutics (OVID), Takeda Pharmaceutical Limited (TAK)

  March 3, 2021
  Tweet Pin It